Table 1.
Clinical characteristics of the sinonasal carcinomas.
| All patients (n=53) | IDH2 mutant (n=18) | SMARCB1-def (n=15) | IDH2/SMARCB1 WT (n=20) | p value | ||
| Sex | ||||||
| Men | 34 (64%) | 12 (67%) | 12 (80%) | 10 (50%) | ||
| Age, median (range, years) | 47 (24–95) | 48 (37–69) | 47 (24–95) | 47 (28–80) | 0.001 | |
| Women | 19 (36%) | 6 (33%) | 3 (20%) | 10 (50%) | ||
| Age, median (range, years) | 63 (30–83) | 51 (43–83) | 66 (53–79) | 64 (30–81) | ||
| T stage | ||||||
| Tis-T3 | 11 (21%) | 16 (33%) | 2 (13%) | 3 (15%) | ||
| T4 | 42 (79%) | 12 (67%) | 13 (87%) | 17 (85%) | ||
| N stage | ||||||
| N0 | 43 (81) | 13 (72%) | 10 (67%) | 20 (100%) | ||
| N1-N2 | 10 (19%) | 5 (28%) | 5 (33%) | 0 | ||
| M stage | ||||||
| M0 | 50 (94%) | 18 (100%) | 14 (93%) | 18 (90%) | ||
| M1 | 3 (6%) | 0 | 1 (7%) | 2 (10%) | ||
| Clinical stage | ||||||
| 0 | 1 (2%) | 1 (6%) | 0 | 0 | ||
| I | 0 | 0 | 0 | 0 | ||
| II | 6 (11%) | 2 (11%) | 1 (7%) | 3 (15%) | ||
| III | 1 (2%) | 1 (6%) | 0 | 0 | ||
| IV | 45 (85%) | 14 (78%) | 14 (93%) | 17 (85%) | ||
| IVA | 16 (30%) | 6 (33%) | 2 (13%) | 8 (40%) | ||
| IVB | 26 (49%) | 8 (44%) | 11 (73%) | 7 (35%) | ||
| IVC | 3 (6%) | 0 | 1 (7%) | 2 (10%) | ||
| Treatment | ||||||
| SxCRT | 28 (53%) | 9 (50%) | 8 (53%) | 11 (55%) | ||
| CRT | 11 (21%) | 5 (28%) | 2 (13%) | 4 (20%) | ||
| SxRT | 8 (15%) | 2 (11%) | 2 (13%) | 4 (20%) | ||
| SxC | 1 (2%) | 0 | 1 (7%) | 0 | ||
| Sx | 3 (6%) | 1 (6%) | 1 (7%) | 1 (5%) | ||
| C | 2 (4%) | 1 (6%) | 1 (7%) | 0 | ||
| Recurrence | ||||||
| All | 35 (66%) | 10 (56%) | 13 (87%) | 12 (60%) | ||
| Local | 22 (46%) | 4 (22%) | 8 (53%) | 10 (50%) | ||
| Regional | 13 (25%) | 5 (28%) | 4 (27%) | 4 (20%) | ||
| Distant | 23 (43%) | 6 (33%) | 9 (60%) | 8 (40%) | ||
| Metastatic sites | ||||||
| Bone | 10 (19%) | 4 (22%) | 3 (20%) | 3 (15%) | ||
| Lung | 8 (15%) | 0 | 7 (47%) | 1 (5%) | 0.002 | 0.011 |
| Neck LN | 7 (13%) | 4 (22%) | 2 (13%) | 1 (5%) | ||
| Liver | 5 (9%) | 3 (17%) | 1 (7%) | 1 (5%) | ||
| Brain | 4 (8%) | 1 (6%) | 3 (20%) | 0 | ||
| Abdominal LN | 3 (6%) | 1 (6%) | 1 (7%) | 1 (5%) | ||
| Mediastinal LN | 3 (6%) | 0 | 3 (20%) | 0 | ||
| Adrenal | 2 (4%) | 1 (6%) | 0 | 1 (5%) | ||
| Parotid | 1 (2%) | 1 (6%) | 0 | 0 | ||
| Soft palate | 1 (2%) | 1 (6%) | 0 | 0 | ||
| Skin | 1 (2%) | 1 (6%) | 0 | 0 | ||
| Mandible | 1 (2%) | 0 | 1 (7%) | 0 | ||
| Pleura | 1 (2%) | 0 | 0 | 1 (5%) | ||
p values compare age of all men and women in the cohort and frequency of lung metastasis between IDH2 mutant and SMARCB1-deficient cases (left) and between SMARCB1-deficient and IDH2/SMARCB1 WT carcinomas (right).
Abbreviations: SMARCB1-def=SMARCB1-deficient sinonasal carcinoma, WT=wild-type, Sx=surgery, C=chemotherapy, RT=radiation therapy, LN=lymph nodes.